TICKERNERD
Menu
CRSPCRSPHealthcare · Biotechnology

CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027

Last close, 24 Aug 2026
$57
−4.08% on the day

The 22 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +40.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.8B
Ticker Nerd rank
31 / 100
Median analyst target
$80
Analysts covering
22
Revenue$10.0M
Operating income−$117.3M
Net income−$91.2M
Free cash flow−$86.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
+22.6%
YTD
+8.8%
1Y
+5.1%
From 52W high
−25.7%
From 52W low
+28.7%
$44
$77
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
69
Value
56
Growth
54
Accruals
50
Volatility
48
Quality
44
Momentum
33
Size
22
Issuance
11

Revisions (69): Analysts have, on balance, been raising their forecasts.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26CRSPHigh $291Median $80Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
13 Buy9 Hold0 Sell
Low $44Median $80High $291

The green dot is the last close — the median target sits +40.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Aug 2026CitigroupMaintainsBuy$82 → $88
8 July 2026HC Wainwright & Co.ReiteratesBuy$80
8 July 2026HC Wainwright & Co.ReiteratesBuy—
6 July 2026CitizensReiteratesMarket Outperform$80
6 July 2026CitizensReiteratesMarket Outperform—
13 May 2026BernsteinMaintainsMarket Perform—
6 May 2026CitigroupMaintainsBuy—
17 Mar 2026Piper SandlerReiteratesOverweight—
17 Feb 2026Chardan CapitalMaintainsBuy—
13 Feb 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026NeedhamMaintainsBuy—
13 Feb 2026TD CowenMaintainsHold—
30 Jan 2026CitizensMaintainsMarket Outperform—
23 Dec 2025CitizensReiteratesMarket Outperform—
23 Dec 2025NeedhamReiteratesBuy—
26 Nov 2025Chardan CapitalMaintainsBuy—
12 Nov 2025CitigroupMaintainsBuy—
11 Nov 2025BairdMaintainsNeutral—
11 Nov 2025RBC CapitalMaintainsSector Perform—
10 Nov 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, CRISPR Therapeutics AG returned +5.1% against +19.6% for the S&P 500, dividends included.

CRSP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Oct 25Jan 26Apr 26Jul 26CRSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
12
Analysts cutting
3
Fundamentals

CRISPR Therapeutics AG (CRSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.2×

Cheaper than 92% of US stocks

Price / sales
429.6×

Cheaper than 2% of US stocks

Price / book
3.3×

Cheaper than 32% of US stocks

EV / EBITDA
−8.1×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
1041.4%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
−302.7%

Higher than 1% of US stocks

Operating margin
−1127.6%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 28% of US stocks

Return on assets
−14.2%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CRISPR Therapeutics AG (CRSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CRISPR Therapeutics AG has a market value of $5.8B and an enterprise value of $4.2B.

  • Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter grew 1041.4% year on year.

  • Net income over the same four quarters: −$451.1M, a −4101.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.76.

  • Free cash flow in the twelve months to 30 June 2026: −$373.8M.

  • Shares outstanding: 96.7M.

  • Trailing P/E: −9.2×; forward P/E: −17.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CRSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRSPCRISPR Therapeutics AG$5.8B
31
LGNDLigand Pharmaceuticals, Inc.$5.6B
73
PTCTPTC Therapeutics, Inc.$5.8B
67
XENEXenon Pharmaceuticals, Inc.$5.8B
49
DFTXDefinium Therapeutics, Inc.$5.8B
40
ERASErasca, Inc.$6.0B
55
DNTHDianthus Therapeutics, Inc.$6.0B
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRSP news & analysis

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research highlighted CRISPR Therapeutics (CRSP), along with NTLA, BEAM and EDIT, as gene-editing biotech stocks worth watching for long-term gains. The report noted that the four companies offer distinct gene-editing opportunities spanning commercial validation, late-stage catalysts and promising early-stage programs.

Why it matters — The item positions CRSP among leading gene-editing biotechs with distinct opportunities, giving CRSP watchers a favorable long-term outlook.

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

The Motley Fool · 21 Aug 2026neutral

The article notes that CRISPR Therapeutics' stock has risen only 8% this year despite the company growing revenue by 1,043% year over year in the second quarter. It highlights that the biotech has one commercial therapy and another therapy nearing phase 3 trials.

Why it matters — CRSP watchers would care because the piece examines whether the gene-editing company's strong revenue growth and pipeline progress justify its modest stock performance this year.

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

Seeking Alpha · 5 Aug 2026positive

An article on Seeking Alpha reiterates a "Strong Buy" rating on CRISPR Therapeutics, citing robust CASGEVY sales growth — $76 million in Q2 2026, up 151% year over year — and pipeline expansion. It notes CASGEVY now targets SCD and TDT patients as young as 2 years old, and that CTX310 showed promising phase 1 results in lipid disorders, with data updates expected at the ESC Congress and in H2 2026.

Why it matters — A CRSP watcher would care because the piece highlights accelerating commercial sales for CASGEVY and near-term in vivo program catalysts that could broaden the company's value beyond gene-edited cell therapies.

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

Zacks Investment Research · 4 Aug 2026positive

CRISPR Therapeutics reported a narrower-than-expected second-quarter loss, with revenues beating estimates as Casgevy sales surged across global markets while its clinical programs advanced.

Why it matters — A CRSP watcher would care because the revenue beat and improved loss signal stronger-than-expected commercial performance for Casgevy alongside continued pipeline progress.

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 3 Aug 2026positive

CRISPR Therapeutics reported a Q2 loss of $0.94 per share, narrower than the Zacks Consensus Estimate of a $1.10 loss and an improvement from the $1.29 per share loss a year earlier. The company topped revenue estimates for the quarter.

Why it matters — The narrower-than-expected loss and revenue beat signal better-than-anticipated financial performance for the quarter, which CRSP watchers would track as a near-term results headline.

FAQ

Frequently asked questions about CRSP stock

What is the CRSP stock price forecast for 2026-2027?

The 22 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRSP stock a buy right now?

Of the 22 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRSP?

As at 22 Aug 2026, CRISPR Therapeutics AG ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (69 of 100).

Will CRSP stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +40.2% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRSP stock forecast for 2030?

No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.

How has CRSP stock performed over the past year?

CRISPR Therapeutics AG returned +5.1% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portfolio of programs across hemoglobin disorders, oncology, regenerative medicine, rare diseases, and autoimmune-related research areas.

What is the latest news on CRSP?

The most recent item we track (Zacks Investment Research, 24 Aug 2026): "4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains". Zacks Investment Research highlighted CRISPR Therapeutics (CRSP), along with NTLA, BEAM and EDIT, as gene-editing biotech stocks worth watching for long-term gains. The report noted that the four companies offer distinct gene-editing opportunities spanning commercial validation, late-stage catalysts and promising early-stage programs.

Company

About CRISPR Therapeutics AG.

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing-based medicines for serious diseases. The company develops therapies using its proprietary CRISPR/Cas9 platform, which enables precise changes to DNA and supports a portfolio of programs across hemoglobin disorders, oncology, regenerative medicine, rare diseases, and autoimmune-related research areas. Its current product set includes approved and investigational cell and gene therapies designed to address conditions with significant unmet medical needs, while its research pipeline spans both ex vivo and in vivo approaches. CRISPR Therapeutics AG also works with strategic partners in biotech and life sciences to advance development and commercialization activities. Headquartered in Zug, Switzerland, the company plays a notable role in the evolving market for gene editing, where its technologies are used to create targeted, next-generation therapeutic candidates.

CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com